NasdaqCM:HSKA

Stock Analysis Report

Executive Summary

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Heska's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.8%

NasdaqCM:HSKA

1.9%

US Medical Equipment

2.1%

US Market


1 Year Return

-26.9%

NasdaqCM:HSKA

13.6%

US Medical Equipment

-0.04%

US Market

HSKA underperformed the Medical Equipment industry which returned 14% over the past year.

HSKA underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

HSKAIndustryMarket
7 Day4.8%1.9%2.1%
30 Day-6.5%-0.2%-3.2%
90 Day0.9%10.2%2.8%
1 Year-26.9%-26.9%14.5%13.6%2.2%-0.04%
3 Year48.8%48.8%70.2%65.0%41.5%32.3%
5 Year451.5%451.5%133.6%106.8%55.0%37.8%

Price Volatility Vs. Market

How volatile is Heska's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Heska undervalued based on future cash flows and its price relative to the stock market?

35%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Heska's share price is below the future cash flow value, and at a moderate discount (> 20%).

Heska's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Heska is overvalued based on earnings compared to the US Medical Equipment industry average.

Heska is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Heska is poor value based on expected growth next year.


Price Based on Value of Assets

Heska is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Heska expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

59.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Heska's revenue is expected to grow by 11.9% yearly, however this is not considered high growth (20% yearly).

Heska's earnings are expected to grow significantly at over 20% yearly.

Heska's revenue growth is expected to exceed the United States of America market average.

Heska's earnings growth is expected to exceed the United States of America market average.

Heska's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Heska is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Heska performed over the past 5 years?

10.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Heska's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Heska's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Heska's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Heska has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Heska used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Heska's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Heska's financial position?


Financial Position Analysis

Heska is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Heska's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Heska's level of debt (10.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (4.6% vs 10.3% today).

Debt is well covered by operating cash flow (26.9%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 245.1x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.7x debt.


Next Steps

Dividend

What is Heska's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Heska's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Heska's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Heska has not reported any payouts.

Unable to verify if Heska's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Heska has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Heska's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Kevin Wilson (47yo)

5.4yrs

Tenure

US$4,754,252

Compensation

Mr. Kevin S. Wilson has been President of Heska Corporation since February 24, 2013. Mr. Wilson has been Chief Executive Officer of Heska Corporation since March 31, 2014. He served as Chief Operating Offi ...


CEO Compensation Analysis

Kevin's remuneration is higher than average for companies of similar size in United States of America.

Kevin's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.4yrs

Average Tenure

49yo

Average Age

The tenure for the Heska management team is about average.


Board Age and Tenure

4.9yrs

Average Tenure

60yo

Average Age

The tenure for the Heska board of directors is about average.


Insider Trading

More shares have been bought than sold by Heska individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$73,79004 Jun 19
Scott Humphrey
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares1,000
Max PriceUS$73.79
SellUS$169,62604 Dec 18
Kevin Wilson
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares1,631
Max PriceUS$105.00
SellUS$312,49504 Dec 18
Jason Napolitano
EntityIndividual
Role
Chief Operating Officer
COO & Chief Strategist
Shares3,000
Max PriceUS$104.41
SellUS$408,00003 Dec 18
G. Gordon
EntityIndividual
Shares4,000
Max PriceUS$102.00
SellUS$18,82430 Nov 18
Kevin Wilson
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares181
Max PriceUS$104.00
SellUS$656,88326 Nov 18
G. Gordon
EntityIndividual
Shares6,700
Max PriceUS$98.69
SellUS$331,99213 Nov 18
Kevin Wilson
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares3,190
Max PriceUS$104.07

Ownership Breakdown


Management Team

  • Jason Napolitano (51yo)

    COO & Chief Strategist

    • Tenure: 3.8yrs
    • Compensation: US$2.51m
  • Nancy Wisnewski (56yo)

    Executive Vice President of Diagnostic Operations & Product Development

    • Tenure: 2.9yrs
    • Compensation: US$2.46m
  • Kevin Wilson (47yo)

    CEO, President & Director

    • Tenure: 5.4yrs
    • Compensation: US$4.75m
  • Rod Lippincott (45yo)

    Executive Vice President of Companion Animal Health Sales

    • Tenure: 6.5yrs
    • Compensation: US$448.50k
  • Steve Asakowicz (53yo)

    Executive Vice President of Companion Animal Health Sales

    • Tenure: 6.5yrs
    • Compensation: US$448.24k
  • Steven Eyl (53yo)

    Executive Vice President of Global Sales & Marketing

    • Tenure: 2.9yrs
    • Compensation: US$309.49k
  • Catherine Grassman (43yo)

    Executive VP & CFO

    • Tenure: 0.3yrs
    • Compensation: US$1.16m
  • Jason Aroesty (44yo)

    Executive Vice President of International Diagnostics

    • Tenure: 1.3yrs
    • Compensation: US$3.56m
  • Jon Aagaard

    Director of Investor Relations

    • Tenure: 0.0yrs
  • Christopher Sveen

    VP & General Counsel

    • Tenure: 0.0yrs

Board Members

  • Mike Furlong (62yo)

    Director

    • Tenure: 0.4yrs
  • Scott Humphrey (48yo)

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: US$120.49k
  • Sharon Riley (58yo)

    Director

    • Tenure: 8.1yrs
    • Compensation: US$137.49k
  • Kevin Wilson (47yo)

    CEO, President & Director

    • Tenure: 5.4yrs
    • Compensation: US$4.75m
  • David Sveen (62yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$108.99k
  • Bonnie Trowbridge (72yo)

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: US$122.99k

Company Information

Heska Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heska Corporation
  • Ticker: HSKA
  • Exchange: NasdaqCM
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$588.251m
  • Shares outstanding: 7.80m
  • Website: https://www.heska.com

Number of Employees


Location

  • Heska Corporation
  • 3760 Rocky Mountain Avenue
  • Loveland
  • Colorado
  • 80538
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSKANasdaqCM (Nasdaq Capital Market)YesPublic Common StockUSUSDJul 1997
HSKNDB (Deutsche Boerse AG)YesPublic Common StockDEEURJul 1997

Biography

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:37
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.